Sanyou Bio closes multi-million-yuan Series A for its innovative antibody drug R&D service platform

Sanyou Bio has completed its Series A financing round raising tens of millions of yuan. This round of financing was jointly invested by Haier Medical and Liferiver Biotech.

Sanyou Bio has completed its Series A financing round raising tens of millions of yuan. This round of financing was jointly invested by Haier Medical and Liferiver Biotech.

Proceeds from this round of financing will be used to upgrade large-capacity phage display full-body and bispecific antibody libraries, improve the in-vitro and in-vitro drug screening service platform, improve drug quality research, process development and production cell line construction and other service platforms, and promote the pre-clinical research of multiple anti-tumor antibody drugs.

Founded in 2015, Sanyou Bio is a bio-high-tech enterprise focused on innovative antibody drug development and services, mainly providing corresponding drug development solutions for biopharmaceutical R&D companies.

To be specific, Sanyou Biotech will cooperate with clients to obtain innovative antibody drug molecules in two modes: first, leverage its leading antibody libraries and integrated R&D capabilities to provide clients with R&D outsourcing services; second, transfer the authorization to clients after independent incubation or cooperative development of antibody molecules.

To date, Sanyou Bio has provided hundreds of innovative antibody drug overall projects or core technical services for more than 100 Chinese and international innovative drug companies, transformed traditional drug giants, emerging biotechnology companies, and well-known research institutions.

It has completed hundreds of antibody screening projects and dozens of overall innovative antibody drug discovery projects.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/23/sanyou-bio-closes-multi-million-yuan-series-a-for-its-innovative-antibody-drug-r-d-service-platform/.

Leave a Reply

Your email address will not be published. Required fields are marked *